Table 1 Clinical and immunological characteristics, treatment, SARS-CoV-2 infection, and psychosocial care at each of the check-ups
Check-up 1 (diagnosis – 6 m) | Check-up 2 (7 m – 12 m) | Check-up 3 (13 m – 24 m) | Check-up 4 (25 m – 36 m) | |
|---|---|---|---|---|
Age (years) Median (IQR) | 3 (1.1–6.05) | 3.75 (1.80–8.08) | 4.95 (2.73–9.03) | 5.95 (4.20–9.08) |
ART | 68/69 (98.55%) | 65/65 (100%) | 64/64 (100%) | 61/61 (100%) |
Good adherence | 57/67 (85.07%) | 52/61 (85.25%) | 53/64 (82.81%) | 55/60 (91.67%) |
CD4 (cells/µl) Median (IQR) | 875 (540–1338) | 1084 (763–1492.5) | 985 (696–1259) | 1102 (821.5–1371.25) |
Viral load < 50 copies/ml | 20/68 (29.41%) | 34/59 (57.63%) | 40/61 (65.57%) | 44/59 (74.57%) |
Opportunistic infections | 28/72 (29.17%) | 8/65 (12.31%) | 4/61 (6.56%) | 4/62 (6.45%) |
SARS-CoV-2 infection | 0/43 (0%) | 0/62 (0%) | 0/41 (0%) | 3/43 (6.98%) |
Clinical stage Na | 9/71 (12.67%) | 7/63 (11.11%) | 7/64 (10.94%) | 7/58 (12.07%) |
Clinical stage Aa | 16/71 (22.53%) | 16/63 (25.40%) | 18/64 (28.13%) | 17/58 (29.31%) |
Clinical stage Ba | 12/71 (16.90%) | 11/63 (17.46%) | 9/64 (14.06%) | 8/58 (13.79%) |
Clinical stage Ca | 34/71 (47.89%) | 29/63 (46.03%) | 30/64 (46.88%) | 26/58 (44.83%) |
Immunological stage 1 | 36/64 (56.25%) | 41/59 (69.49%) | 42/57 (73.68%) | 46/56 (82.14%) |
Immunological stage 2 | 17/64 (26.56%) | 16/59 (27.12%) | 11/57 (19,30%) | 8/56 (14.29%) |
Immunological stage 3 | 11/64 (17.19%) | 2/59 (3.39%) | 4/57 (7.12%) | 2/56 (3.57%) |
P < 3 weight¥ | 13/46 (28.26%) | 3/38 (7.89%) | 2/30 (6.67%) | 3/24 (12.5%) |
P > 97 weight¥ | 1/46 (2.17%) | 1/38 (2.63%) | 0/30 (0%) | 0/24 (0%) |
P < 3 height¥ | 23/45 (51.11%) | 16/38 (42.11%) | 9/30 (30%) | 8/24 (33.33%) |
P > 97 height¥ | 0/45 (0%) | 0/38 (0%) | 0/30 (0%) | 0/24 (0%) |
BMI Median (IQR)¥ | 15.70 (15.09–16.90) | 16.19 (14.95–17.72) | 16.29 (14.48–17.21) | 16.30 (15.31–17.41) |
P < 3 BMI§ | 1/21 (4.17%) | 1/24 (4.17%) | 1/31 (3.23%) | 1/36 (2.78%) |
P > 85 BMI§ | 2/21 (8.33%) | 4/24 (16.67%) | 4/31 (12.90%) | 3/36 (8.33%) |
Pathological psychomotor development | 12/69 (17.39%) | 10/65 (15.38%) | 9/64 (14.06%) | 5/61 (8.20%) |
Correct vaccination | 36/53 (67.92%) | 33/47 (70.21%) | 34/44 (77.27%) | 33/41 (80.49%) |
COVID-19 vaccine | 1/36 (2.78%) | 0/30 (0%) | 3/35 (8.57%) | 5/35 (14.29%) |
COVID-19 vaccine type | Comirnaty (Pfizer-BioNTech) | 2 × Comirnaty (Pfizer-BioNTech) CoronoVac (Sinovac Biotech) | 3 × Comirnaty (Pfizer-BioNTech) 2 × CoronoVac (Sinovac Biotech) |